Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Oct 24, 2025; 16(10): 112392
Published online Oct 24, 2025. doi: 10.5306/wjco.v16.i10.112392
Published online Oct 24, 2025. doi: 10.5306/wjco.v16.i10.112392
Ropeginterferon alfa-2b vs standard therapy in polycythemia vera: A meta-analysis of efficacy and safety outcomes
Leo Tom, Department of Clinical Oncology, K S Hegde Medical Academy, Mangalore 575018, Karnātaka, India
Shinjit Mani, Department of Medical Oncology, Chittaranjan National Cancer Institute, Kolkata 700160, West Bengal, India
Akash Rawat, Department of General Medicine, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Dehra Dun 248016, Uttarākhand, India
Mina Nan, Department of Internal Medicine, Capital Health Regional Medical Center, NJ 07002, Trenton, United States
Shruti Manoj Mundada, Department of Clinical Oncology, Gandhi Medical College and Hospital, Hyderabad 500003, Telangāna, India
Basel Al Khatib, Department of Clinical Oncology, Alfaisal University, Riyadh 11533, Saudi Arabia
Aparna Gopinath, Department of Clinical Oncology, Government Medical College Trivandrum, Thiruvananthapuram 695011, Kerala, India
Osama Taj, Department of Clinical Oncology, Creek General Hospital, Karachi 75190, Sindh, Pakistan
Namitha Salahuddin, Department of Clinical Oncology, Gulf Medical University, Ajman 4184, United Arab Emirates
Farzana Shaju, Department of Clinical Oncology, Sree Narayana Institute of Medical Sciences, Ernakulam 683594, Kerala, India
Syeda Parsa, Department of Clinical Oncology, Chandka Medical College, Sindh 77280, Pakistan
Mahmud Abdurrahman, Department of Clinical Oncology, Richmond Gabriel University, Kingstown VC0100, Saint George, Saint Vincent and the Grenadines
Ashesh Das, Department of Clinical Oncology, KPC Medical College and Hospital, Kolkata 700001, West Bengal, India
Mirza Muhammad Hadeed Khawar, Department of Clinical Oncology, Services Institute of Medical Sciences, Lahore 40050, Punjab, Pakistan
Ali Sher, Department of Clinical Oncology, International University of Kyrgyzstan, ISM IUK Eastern Campus, Bishkek 720054, Chüy, Kyrgyzstan
Co-first authors: Leo Tom and Shinjit Mani.
Author contributions: Tom L and Mani S contribute equally to this study as co-first authors; Tom L was responsible for conceptualization, methodology, formal analysis, investigation, data curation, writing - original draft, visualization, project administration; Mani S was responsible for methodology, investigation, data curation, writing - review & editing, validation; Rawat A was responsible for methodology, formal analysis, investigation, data curation, writing - review & editing, visualization; Nan M was responsible for investigation, data curation, writing - review & editing, validation; Al Khatib B was responsible for methodology, investigation, data curation, writing - review & editing, supervision; Gopinath A was responsible for investigation, data curation, writing - review & editing; Mundada SM was responsible for investigation, data curation, writing - review & editing; Taj O was responsible for investigation, resources, writing - review & editing; Salahuddin N was responsible for investigation, visualization, writing - review & editing; Shaju F was responsible for investigation, resources, writing - review & editing; Parsa S was responsible for investigation, data curation, writing - review & editing; Abdurrahman M was responsible for methodology, validation, writing - review & editing, supervision; Das A was responsible for formal analysis, investigation, validation, writing - review & editing; Khawar MMH was responsible for investigation, resources, writing - review & editing; Sher A was responsible for conceptualization, methodology, supervision, project administration, writing - review & editing; all authors read and approved the final manuscript.
Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ali Sher, MD, Department of Clinical Oncology, International University of Kyrgyzstan, ISM IUK Eastern Campus, 1F Intergelpo Street, Bishkek 720054, Chüy, Kyrgyzstan. aligondal78679@gmail.com
Received: July 28, 2025
Revised: August 4, 2025
Accepted: September 26, 2025
Published online: October 24, 2025
Processing time: 90 Days and 17.3 Hours
Revised: August 4, 2025
Accepted: September 26, 2025
Published online: October 24, 2025
Processing time: 90 Days and 17.3 Hours
Core Tip
Core Tip: Ropeginterferon alfa-2b significantly enhances complete hematologic and molecular responses in polycythemia vera compared to standard therapy, reducing phlebotomy needs without increasing thrombotic risk. However, higher adverse event-related discontinuations necessitate careful patient monitoring. Despite robust study designs, heterogeneity and potential publication bias warrant cautious interpretation. Long-term studies are essential to refine dosing and improve tolerability for optimal patient outcomes.